gested by these clinical experts. The resulting health states (n = 17) were piloted and used in a societal-based valuation study (n = 100). Participants rated half of the total health states in a standard gamble interview to derive health state utility scores. Data were analysed using a mixed model analysis. This study was conducted in line with standard NICE appraisal methodology. RESULTS: All tumour response statuses and toxicities were independent significant predictors of utility (p < 0.001). Stable disease with no toxicity (our base state) had a utility value of 0.65. Utility scores ranged from 0.67 (responding disease with no toxicity) to 0.47 for progressive disease. CONCLUSION: This study reflects the value that society places on the avoidance of disease progression and severe toxicities associated with the treatment of second-line advanced NSCLC.
PCN70

RELIABILITY AND VALIDITY OF HEALTH UTILITIES INDEX (HUI) SCORES FOR SURVIVORS OF BRAIN TUMORS IN CHILDHOOD: AGREEMENT BETWEEN PATIENTS AND PARENTS
Horsman JR 1 , Spitzer R 2 , Hsu T 1 , Duckworth J 3 , Barr RD 1 , Furlong W 1 1 McMaster University, Hamilton, ON, Canada, 2 University of Toronto, Toronto, ON, Canada, 3 McMaster Children's Hospital, Hamilton, ON, Canada OBJECTIVES: Assess inter-rater agreement (patient and parent) of HUI utility scores for survivors of brain tumors in childhood. METHODS: Patients and their parents were interviewed twice using an interviewer-administered HUI questionnaire. Agreement was assessed using intra-class correlation coefficients (ICC). T-tests assessed the statistical significance of differences in mean overall and pain utility scores between patients reporting no pain and those reporting pain. RESULTS: HUI data for 40 brain tumor survivors (57.5% female) were collected during late 2000 and early 2001 (interview 1). To date, 26 re-assessment interviews have been completed during 2005-2006 (interview 2). One patient has died. Patient mean age was 6.8 years at diagnosis and 16.2 years at the first survey. For overall health-related quality of life scores (HRQL), there was substantial inter-rater agreement (HUI3 ICC = 0.723, p < 0.001) at interview 1 and moderate agreement (HUI3 ICC = 0.561, p = 0.03) at interview 2. There was substantial to almost perfect agreement at both interviews for attributes considered readily observable (vision, speech, ambulation and dexterity) (ICC 0.783 to 0.988, p < 0.001). For less observable attributes (emotion, cognition, pain), agreement was moderate or less (ICC from 0.101 to 0.611, p = 0.372 to 0.002). Statistically significant differences were detected for both mean HRQL (difference = 0.36, p = 0.003) and pain (difference = 0.24, p = 0.003) scores between patients reporting pain (n = 14) and those pain free at interview 1. At interview 2, the mean scores were not statistically significantly different between patients reporting pain (n = 7) and those with no pain (n = 19, HRQL p = 0.317; pain attribute p = 0.067). CON-CLUSIONS: There was moderate or better inter-rater agreement for HRQL and all readily observable single-attribute HUI3 scores both at interview 1 and interview 2. Levels of ICC are consistent with previous studies of childhood cancer survivors in Brazil and Uruguay. Differences in mean HRQL and pain scores between patients with and without pain is evidence of discriminative validity.
PCN71 PSYCHOMETRIC EVALUATION OF A PATIENT REPORTED OUTCOME QUESTIONNAIRE FOR METASTATIC COLORECTAL CANCER
Mathias SD 1 , Pritchard ML 1 , Mathias SD 1 , Lu ZJ 2 , Wright N 3 1 Ovation Research Group, San Francisco, CA, USA, 2 Amgen, Inc, Thousand Oaks, CA, USA, 3 Amgen, Inc, Cambridge, England OBJECTIVES: Assess the reliability and validity of a newly developed patient-reported outcome (PRO) questionnaire for metastatic colorectal cancer (mCRC) patients. METHODS: The questionnaire, which includes five scales [NCCN/FACT Colorectal Cancer Scale (CS), De Novo Bother Life Quality Index (DNB), EORTC QLQ-C30 Global Quality of Life Subscale (EORTC), EQ-5D Index Scale (EQ-5D) and the EQ-5D visual analog scale (VAS)], was administered every four weeks to mCRC patients in a Phase III clinical trial. Its psychometric properties were evaluated, including internal consistency reliability, test-retest reliability, construct validity, known groups validity, and responsiveness. RESULTS: A total of 391 mCRC patients completed the questionnaire at baseline and at least one followup assessment. Internal consistency was demonstrated with Cronbach's alphas for all scales >0.70 (range: 0.81-0.92). The 4-week test-retest reliability, as measured by the intra-class correlation, among patients who had stable EQ-5D scores and also among patients whose ECOG performance status was unchanged, ranged from 0.58-0.76 and 0.61-0.76, respectively. Construct validity was demonstrated based on proposed interscale correlations being borne out [e.g., CS was highly correlated with EORTC (0.72)]. Known groups validity was evaluated by examining the scale scores of patients categorized by their ECOG performance status. Other than DNB, patients with better performance status reported better scores than those with a lower performance status (ECOG = 0 or 1 vs. 2). Significant differences were reported on all scales (p < 0.001) at baseline and week 8 with the exception of DNB. Responsiveness, as measured by Guyatt's statistic, was >0.20 for all scales from baseline to week 8 (range 0.56-1.13) and from weeks 4 to 12 (range 0.29-1.11). EORTC and EQ-5D Index scales were the most responsive. CONCLUSIONS: Results provide preliminary evidence of the reliability, validity, and responsiveness of the questionnaire. Additional work is needed to estimate the minimal clinical important difference and more fully investigate test-retest reliability.
PCN72 A COMPARISON OF PATIENT REPORTED OUTCOMES ACROSS CURATIVE TREATMENTS OF ELDERLY PROSTATE CANCER PATIENTS
Jayadevappa R, Chhatre S, Wein AJ, Malkowicz SB University of Pennsylvania, Philadelphia, PA, USA OBJECTIVE: We examined demographics, clinical characteristics, Health Related Quality of Life (HRQoL) and satisfaction with care across two treatments (radical prostatectomy or RP and external beam radiation or EBRT) for older prostate cancer (PCa) patients. METHODS: In this prospective cohort study we recruited 215 newly diagnosed PCa patients, 65 years or older, from the urology clinics of an urban academic hospital and a VA hospital. Patients completed generic (SF-36), prostate specific (UCLA-PCI) HRQoL, and satisfaction with care (CSQ-8) surveys prior to treatment and at 3, 6, and 12 months posttreatment. Clinical and demographic data were obtained using hospital based databases. Repeated measures ANOVA was used to examine changes in generic and PCa specific HRQoL across treatments. Log-linear regression was used to determine factors associated with 12 month HRQoL. Survival curves were used to
